Medical instrument company: HOLX (HOLX) (1985)

Hologic Inc. (NASDAQ: HOLX) was founded in 1985 and is headquartered in Bedford, Massachusetts, USA. It has 5,333 full-time employees. It is a medical equipment manufacturer and a global company. A leader in the research and development of digital innovative imaging technology.

Hologic HOLX Logo

HOLX Hologic (HOLX):

Hologic, Hologic, develops, produces and sells diagnostic products, medical imaging systems and women’s surgical examination products in the United States and the world, and is among the top three global molecular diagnostic companies (respectively: Roche , Illumina and Hologic). Holojet occupies the world’s number one position in nine technical fields serving women’s health , including: breast cancer diagnosis and treatment, cervical cancer screening, prenatal testing and osteoporosis testing .

Hologic operates in 4 departments: diagnosis, breast care, gynecological surgery and bone health.

  • Diagnostics department-provides APTIMA home experiment, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybrid protection and dual kinetic analysis, instrumentation, chemical aggressor platform, new Bai’s system, fetal fibronectin test, Family Procleix test, virology and infectious disease products, etc.
  • Breast health department-provides breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) breast imaging systems; breast biopsy (biopsy) equipment; breast biopsy sites Marking and guidance system; Breast brachytherapy products; Mammography two-dimensional and three-dimensional image acquisition and display system; C-view; photosensitive coating.
  • Gynecological Surgery Department-Provides NovaSure system to treat women with abnormal uterine bleeding; MyoSure system, hysteroscopic resection of fibroids; Hao Luojie’s clinically proven product portfolio provides necessary tools to help detect and prevent cervical cancer. When used, ThinPrep ® New Pap smear test, ThinPrep imaging system and Cervista ® HPV test can help you identify women at high risk of cervical cancer so that you and your patients can make informed decisions and make cervical cancer screening smarter.
  • Bone Health Department——Provide the development of horizon X-ray system bone densitometer (such as Hologic Sahara ultrasonic bone densitometer) to evaluate and detect the fracture site and bone density; mini C-arm imaging system to perform a patient’s Minimally invasive surgery on limbs, such as hands, wrists, knees, feet and ankles.

In addition, Haolojie also provides laboratory equipment. Haolojie has been committed to providing the laboratory with the latest and most effective technology and first-class customer service. Its ThinPrep ® New Pap smear examination started a revolution in New Pap smear examination 10 years ago. Today, its ThinPrep New Pap smear analysis system has gradually become a new medical standard. ThinPrep’s image analysis system uses computer technology to automatically scan every cell and cell cluster and highlight the area of ​​interest for manual analysis. This dual-reading technology that combines computer imaging technology with human experience improves the screening effect, and at the same time focuses manual interpretation skills on areas that are difficult to explain by computer analysis alone: ​​the cells that are most worthy of attention.

The Cellient ® automated cell block system is the first fully automated cell block system. Vacuum-assisted filtration will agglutinate the available cells in the cell clumps to produce high-quality, diagnostically significant cell clumps that can be used for effective inspection-the entire process takes less than one hour.

Shangju Industrial Medical (Haoluojie) Hologic Company sells its products through a network of direct sales, independent distributors and sales representatives, forming a strategic alliance with Quest Diagnostics.

Hologic (HOLX) memorabilia:

  • In 1985, it was first approved by the FDA to use DNA probe technology for clinical diagnostic testing, and the first-generation product, the mycoplasma tissue culture test, was introduced in the United States.
  • In 1987, the initial public offering (IPO) was completed, raising 16.2 million US dollars.
  • In 1988, the PACE® testing reagent was officially launched, which is the first-generation testing equipment for two popular sexually transmitted diseases, namely CT and GC.
  • In 1989, the ribosomal ribonucleic acid (rRNA) test method was awarded the first US patent mark, which is also the basis of Gen-Probe. The first batch of four AccuProbe culture certification testing reagents was approved by the FDA.
  • In 1994, four products were launched in the United States: Direct Detection Reagent for Streptococcus A (GASDIRECT®), PACE® 2 Combination Detection Reagent for CT and GC, Probe Competitive Validation Detection Reagent for CT and GC Probe Competition Validation Detection Reagent .
  • In 1995, the proprietary DNA sequence amplification technology was granted a US patent and TMA (transcription-mediated amplification technology) was launched.
  • In 1996, the AMPLIFIED Mycobacterium tuberculosis complex nucleic acid detection reagent (TMA hybridization method) ® was officially launched in the United States; the FDA first approved nucleic acid amplification technology for testing Mycobacterium tuberculosis.
  • In 2001, the FDA approved the sale of APTIMACombo 2® assay.
  • In 2002, the FDA approved the use of the PROCLEIX® reagent developed by Gen-Probe for simultaneous detection of human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) in blood banks. The DTS® 800 system was officially launched and applied to APTIMA Combo 2® reagents for automated processing.
  • In 2003, MLT was acquired (the technology developed by MLT is the basis of Gen-Probe chemiluminescence hybridization protection assay (HPA) inspection technology). The FDA approved the use of the fully automated TIGRIS® DTS® system developed by Gen-Probe for sexually transmitted disease testing. Approval of TIGRIS system to run APTIMA COMBO 2® reagent.
  • In 2005, the FDA approved the marketing authorization of APTIMA® reagent to detect Neisseria gonorrhoeae (GC). Granted US marketing authorization to use APTIMA Combo 2® to detect Chlamydia trachomatis and Neisseria gonorrhoeae in liquid pasteurized samples collected and processed by Cytyc’s ThinPrep® 2000 system. President Bush awarded Gen-Probe the highest honor in the field of national technological innovation in 2004-the US National Technology Award, in recognition of Gen-Probe’s pioneering work in the field of research and development of innovative nucleic acid assays to ensure that the national donor blood is free of HIV-1 virus and C Hepatitis B virus.
  • In 2006, the FDA granted a marketing license for APTIMA® HIV-1 RNA quantitative reagent (at the same time it obtained a patent).
  • In 2007, the FDA approved the PROCLEIX®TIGRIS® system (the first fully automated molecular diagnostic instrument) to screen donor blood, organs and tissues for West Nile Virus (WNV) with the help of the PROCLEIX WNV assay.
  • In 2008, the FDA fully approved the use of PROCLEIX® ULTRIO in the TIGRIS system to detect HIV-1, HCV and HBV in donor blood.
  • In 2009, it spent US$136 million in cash to acquire Tepnel Life Sciences; the company is located in Europe and has a rapid rise in the field of molecular diagnostics, with the transplant diagnostic business particularly prominent. (The US and European patent authorities granted Gen-Probe seven patents in other fields, expanding its intellectual property portfolio in the field of automated nucleic acid detection reagents.)
  • In 2010, it acquired Prodesse for US$60 million in cash, which used to be a leader in molecular testing for respiratory infections.
    In 2011, the FDA approved Gen-Probe’s APTIMA® HPV assay, which is a new molecular test reagent for detecting cervical cancer-induced viruses.
  • In 2012, the FDA approved the PROGENSAPCA3 reagent and PANTHER system.
  • In April 2012, Hologic acquired Gen-Probe for US$3.72 billion (US$82.75 per Gen-Probe stock, a 20% premium).
  • In April 2013, Hologic opened an official WeChat account to focus on women’s health (but it will not be updated after October 2, 2013).
  • On December 15, 2016, Grifols, SA (GRFS) confirmed the acquisition of Hologic (HOLX)’s shares in its joint venture. GRFS will complete the acquisition with a long-term loan of US$1.7 billion and existing book cash (a total of US$1.85 billion).
Notify of
Inline Feedbacks
View all Intels

Electricity and gas utility company: Dominion Energy (D) (1909)

Cloud computing business software company: Anaplan Inc. (PLAN)